...
首页> 外文期刊>Materials science & engineering >In vitro synergic activity of diethyldithiocarbamate and 4-nitrochalcone loaded in beeswax nanoparticles against melanoma (B16F10) cells
【24h】

In vitro synergic activity of diethyldithiocarbamate and 4-nitrochalcone loaded in beeswax nanoparticles against melanoma (B16F10) cells

机译:含二乙基二硫代氨基甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸乙酯的体外协同活性叶片纳米粒子(B16F10)细胞

获取原文
获取原文并翻译 | 示例
           

摘要

The use of nanoparticles as drug delivery systems to simultaneously carry several therapeutic agents is an attractive idea to create new synergic treatments and to develop the next generation of cancer therapies. Therefore, the goal of this study was the simultaneous encapsulation of a hydrophilic drug, sodium diethyldithiocarbamate (DETC), and a hydrophobic drug, 4-nitrochalcone (4NC), in beeswax nanoparticles (BNs) to evaluate the in vitro synergic activity of this combination against melanoma (B16F10) cells. BNs were prepared by water/oil/water double emulsion in the absence of organic solvents. Transmission electron microscopy imaging and dynamic light scattering analyses indicated the formation of BNs with a semispherical shape, average diameter below 250 nm, relatively narrow distributions, and negative zeta potential. The double emulsion technique proved to be effective for the simultaneous encapsulation of DETC and 4NC with efficiencies of 86.2% and 98.7%, respectively, and this encapsulation did not affect the physicochemical properties of the BNs. DETC and 4NC loaded in BNs exhibited a higher cytotoxicity toward B16F10 cells than free 4NC and DETC. This simultaneous encapsulation led to a synergic effect of DETC and 4NC on B16F10 cells, decreasing the cell viability from 46% (DETC BNs) and 54% (4NC BNs) to 64% (DETC+4NC BNs). Therefore, the IC50 of DETC+4NC was also lower than that of either when individually encapsulated, and that of free DETC or 4NC. Therefore, DETC and 4NC were efficiently simultaneously encapsulated in BNs and this drug combination was able to generate an in vitro synergic therapeutic effect on B16F10 cells.
机译:使用纳米颗粒作为药物递送系统,同时携带几种治疗剂是一种有吸引力的想法,可以创造新的协同治疗和发展下一代癌症疗法。因此,本研究的目的是同时包封亲水药物,二乙基硫代氨基甲磺酸钠(DETC)和疏水药物,4-硝基棱镍(4NC),在Beeswax纳米粒子(BNS)中,以评估这种组合的体外协同活性对抗黑色素瘤(B16F10)细胞。在没有有机溶剂的情况下,通过水/油/水双乳液制备BNS。透射电子显微镜成像和动态光散射分析表明BNS的形成具有半球形,平均直径低于250nm,分布相对窄和负Zeta电位。被证明的双乳液技术分别对效率同时封装了86.2%和98.7%的效率,并且该包封不影响BNS的物理化学性质。在BNS中加载的DETC和4NC朝向B16F10细胞的较高的细胞毒性而不是自由4NC和DETC。这种同时封装导致DETC和4NC对B16F10细胞的协同作用,将细胞活力从46%(DETC BNS)和54%(4NC BNS)降低至64%(DETC + 4NC BNS)。因此,DETC + 4NC的IC 50也低于单独封装时的IC50,以及免费的DETC或4NC的IC50。因此,DEDC和4NC在BNS中有效地包封,该药物组合能够在B16F10细胞上产生体外协同治疗效果。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号